

## CFAVax

### CFA - Complete Freund's Adjuvant

#### Product information and content

**CFAVax** Complete Freund's adjuvant (CFA) is a water-in-oil emulsion containing *Mycobacterium Tuberculosis* (1mg/mL).

**CFAVax** is available in three quantities: #CFA0010: 10 mL, #CFA0050: 5x10 mL & #CFA0100: 10x10 mL.

#### Storage and stability

Store CFA at +4°C away from light. Do not freeze.

#### Description

Complete Freund's Adjuvant (CFA) is a water-in-oil emulsion containing 1 mg per mL heat-killed dried *Mycobacterium tuberculosis*. CFA and IFA are among the most used adjuvants and have been used extensively in experimental immunology. Complete Freund's Adjuvants has been used for decades in practical veterinary vaccination.

CFAVax consists of a mixture of mineral oil and emulsifier in a ratio of 85% v/v oil and 15% v/v emulsifier. Each 10 mL CFA vial contains 10 mg *mycobacterium*. Importantly, the CFAVax is not a pre-formed emulsion and thus it must be mixed with an equal volume of aqueous solution of antigen and subsequently emulsified prior to use. The emulsifier is mannide monooleate, an ester consisting of mannitol as the hydrophilic residue and oleic acid (unsaturated C18 fatty acid) as the hydrophobic part. Even if the mechanisms of action of oil emulsions are still poorly understood, some evidences suggest a partial requirement for NOD2. Moreover, these emulsions are prone to cause cellular damage upon injection and thus, endogenous signals released during necrotic cell death may also contribute to their adjuvant activity. Immune response is dramatically enhance by the presence of the mycobacterial component that attracts macrophages and immune cells at the site of injection. CFA induces principally a Th1 response and can cause granulomas and an intense inflammatory reaction at the inoculation site.

Freund's adjuvant is designed to provide continuous release of antigens necessary for stimulating strong persistent immune response.

The use of CFA should be used responsibly and with care in order to avoid or minimize the adverse effects of excessive inflammation.

For most applications, CFA is usually only necessary for the initial immunization, while IFA is the adjuvant of choice for subsequent immunizations.

#### Method/protocol

##### Recommendations before starting:

The inoculum should be free of extraneous microbial contamination; filtration of the antigen before mixing with the adjuvant is recommended.

Injections containing Complete Freund's Adjuvant should be given subcutaneously; it is recommended to divide the inoculum containing the adjuvant into fractions so that not more than 0.1 mL is injected per site in mice or rats and 0.25 mL per site for rabbits. If skin necrosis results while following these guidelines, future injections should be spaced farther apart.

1. Vortex the vial to re-suspend the mycobacterium.
2. Prepare 1 mL of CFAVax adjuvant in a plastic 3 cc luer-lock syringe
3. Dilute the antigen mixture in saline buffer or phosphate buffer for a final immunogen concentration of 10-100 µg/100 µL (sufficient for immunizing mice, rats and rabbits).
4. Prepare 1 mL of antigen in a plastic 3 cc luer-lock syringe
5. Form an emulsion:
  - a. Connect the two syringes using a double-ended locking connector
  - b. Press syringe barrels back and forth, transferring contents from one syringe to the other. A white emulsion should form immediately
  - c. Mix for 5 to 10 min: a stable emulsion is produced
  - d. The resulting emulsion should appear white, be stable and should not disperse when dropped into water

NOTE: for smaller volumes, a prolonged mixing can be performed by vigorously pipetting or vortexing. For larger volumes use a tissue homogenizer to form the emulsion.

6. Separate the syringes and remove air before attaching the needle (21g for mice or rats; 19g for rabbits)
7. Inject into the animal according to the table below; the volume depends on the site of injection.
8. It is necessary to separate multiple injection sites by a distance sufficient to avoid coalescence of inflammatory lesions.

NOTE: Preferential route of administration for Freund's adjuvant should be subcutaneous as it is the less disruptive. Other routes can be used: intramuscular, intradermal or intraperitoneal.

Species	SC	IM	ID	IP	IV
<b>Mice</b>	0.1 mL/site 4 sites max.	N.R.	N.R.	0.25 mL max.	N.A.
<b>Rats</b>	0.1 mL/site 2 sites max.	N.R.	0.1 mL/site 8 sites max	0.5 mL max.	N.A.
<b>Rabbits</b>	0.25 mL/site 8 sites max.	0.25 mL/site 2 sites max	0.1 mL / site 12 sites max	N.R.	N.A.


SC = SC = Subcutaneous, IM = Intramuscular, ID = intradermal, IP = intraperitoneal,

IV = IV = intravenous, N.R. = not recommended, N.A. = not acceptable


**Table 1:** Recommended volume of Freund's Adjuvant/Antigen emulsion per route of injection for different animal species (Adapted from Hendriken CFM et Hau J., 2003, in handbook of laboratory animal science vol I).

## Results

Results presented below demonstrate the effect of CFA adjuvant on immune system response:



**Figure 1.** Immune response in mice immunized with ovalbumin (OVA) or OVA+CFA. (A) mean concentrations (mg/mL) in Mice serum of OVA-IgE after IP OVA immunization without adjuvant (OVA/Sal), alum (OVA/Alum) or CFA (OVA/CFA). (B) Mean total number of macrophages, eosinophils, neutrophils and lymphocytes in BAL fluid of mice after IP OVA immunization without adjuvant (OVA/Sal), alum (OVA/Alum) or CFA (OVA/CFA) (adapted from Nakada et al. Respiratory research 2014;15:90)



**Figure 2.** CFA adjuvant favors a strong Th1 response. BALB/c mice were immunized with OVA+IFA or OVA+CFA and draining lymph nodes were harvested 7 days later. (A) IFN- $\gamma$  and (B) IL-4 production was measured by ELISA after 72H in vitro incubation with OVA. (adapted from Shibaki et al. Exp Derm. 2002;11:163-134).

## Example of protocol:

### Immunization of mice for production of antigen-specific antibodies

This rapid protocol describes immunization of mice with Freund's adjuvants/Ovalbumin antigen emulsion to induce high production of antibodies specific for an antigen. Mice are immunized with OVA emulsified in Complete Freund's Adjuvant (CFA), followed by a booster dose of protein emulsified in Incomplete Freund's Adjuvant (IFA).

1. Authorize the mice to acclimatize to the animal facility at least 7 days before immunization.
2. Dilute the antigen to a concentration of 100  $\mu$ g in 100  $\mu$ L of saline buffer
3. Prepare OVA/CFA emulsion as described in protocol using 2 lock-luer syringes for a better emulsion stability.
4. Day 1: Inject mice with 0.1 mL of antigen emulsified in CFA at two sites subcutaneously on the back of the mice (total 0.2 mL per mouse)  
NOTE: Keep the needle inserted into the subcutaneous space for 10 to 15 seconds after each injection to avoid leakage of the emulsion. Withdraw the needle very precasiously.
5. Day 14: Administrate a booster injection of 0.1 mL of antigen emulsified in IFA subcutaneously at one site  
NOTE: it is recommended to collect a serum sample and test the antibody concentration 7 to 10 days after the boost injection. If the concentration is lower than expected, an additional booster dose of IFA emulsion may be given 14 days after.
6. Collect serum 7 to 14 days after administration of the last dose and purify antibodies.

## Purchaser Notification

### Limited License

The purchase of the CFAVax Adjuvant grants the purchaser a non-transferable, non-exclusive license to use the included components. This reagent is intended for in-house research only by the buyer. Such use is limited to the transfection of nucleic acids as described in the product manual. In addition, research only use means that this formulation is excluded, without limitation, from resale, repackaging, or use for the making or selling of any commercial product or service without the written approval of OZ Biosciences.

Separate licenses are available from OZ Biosciences for the express purpose of non-research use or applications of the CFAVax Adjuvant. To inquire about such licenses, or to obtain authorization to transfer or use the enclosed material, contact the Director of Business Development at OZ Biosciences.

Buyers may end this License at any time by returning all CFAVax Adjuvant material and documentation to OZ Biosciences, or by destroying CFAVax Adjuvant components. Purchasers are advised to contact OZ Biosciences with the notification that a CFAVax Adjuvant is being returned in order to be reimbursed and/or to definitely terminate a license for internal research use only granted through the purchase of the kit(s).

This document covers entirely the terms of the CFAVax Adjuvant research only license, and does not grant any other express or implied license. The laws of the French Government shall govern the interpretation and enforcement of the terms of this License.

### Product Use Limitations

The CFAVax Adjuvant is developed, designed, intended, and sold for research use only. It is not to be used for human diagnostic or included/used in any drug intended for human use. All care and attention should be exercised in the use of the component by following proper research laboratory practices

#### OZ Biosciences SAS

163 avenue de Luminy  
Case 922, zone entreprise  
13288 Marseille cedex 09 - FRANCE  
Ph: +33 (0) 486 948 516  
Fax: +33 (0) 463 740 015  
contact@ozbiosciences.com  
order@ozbiosciences.com

#### OZ Biosciences INC

7975 Dunbrook Road,  
Suite B  
San Diego CA 92126- USA  
Ph: + 1-858-246-7840  
Fax: + 1-855-631-0626  
contactUSA@ozbiosciences.com  
orderUSA@ozbiosciences.com

Rev 10/20 FB